Low levels of high-density lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: A post-hoc analysis from the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug E
about
HDL as a prognostic biomarker for coronary atherosclerosis: the role of inflammation.PLTP activity inversely correlates with CAAD: effects of PON1 enzyme activity and genetic variants on PLTP activityImpact of estimated HDL particle size via the ratio of HDL-C and apoprotein A-I on short-term prognosis of diabetic patients with stable coronary artery disease.Prevalence of conventional risk factors and lipid profiles in patients with acute coronary syndrome and significant coronary diseaseRelationship of high-density lipoprotein cholesterol with periprocedural myocardial injury following elective percutaneous coronary intervention in patients with low-density lipoprotein cholesterol below 70 mg/dL.Alterations in lipid transfers to HDL associated with the presence of coronary artery disease in patients with type 2 diabetes mellitusAssociation Between Paradoxical HDL Cholesterol Decrease and Risk of Major Adverse Cardiovascular Events in Patients Initiated on Statin Treatment in a Primary Care Setting.The clinical value of metabolic syndrome and risks of cardiometabolic events and mortality in the elderly: the Rotterdam study.Roles of High-Density Lipoprotein Cholesterol in Patients With Acute Myocardial Infarction.Dietary supplementation with either saturated or unsaturated fatty acids does not affect the mechanoenergetics of the isolated rat heartHDL hypothesis: where do we stand now?HDL: to treat or not to treat?High-density lipoprotein, beta cells, and diabetes .Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options.Low Levels of High-Density Lipoprotein Cholesterol Do Not Predict the Incidence of Type 2 Diabetes in an Iranian High-Risk Population: The Isfahan Diabetes Prevention Study.Association Between Very Low Levels of High-Density Lipoprotein Cholesterol and Long-term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the TRILOGY ACS Trial.Nicotinic acid: current status in lipid management and cardiovascular disease prevention.Duration-response association between exercise and HDL in both male and female Taiwanese adults aged 40 years and above.Impact of red blood cells count on the relationship between high density lipoproteins and the prevalence and extent of coronary artery disease: a single centre study [corrected].The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: Implications for coronary atheroma progression and cardiovascular events.Novel findings in relation to multiple anti-atherosclerotic effects of XueZhiKang in humans.
P2860
Q30251918-DEB2D4E7-843B-442D-BD91-FD626F876734Q30655573-6FE8773E-4BCE-4905-A079-5B40FBD1978BQ34260460-EFD10FCC-D1FF-4EE2-A4D4-A4AA2CD5CCE3Q34351193-DDBC6611-BB07-41E8-AC2E-6FD7B3544208Q35088129-34C6DFD9-3E1C-451B-A47B-04023AB6690FQ35950004-4D75DA6C-CCE6-4993-8F94-10FA96688310Q36599589-C4AA2DAF-F0B1-480C-8ECA-6FED6C5E81C4Q36842540-CA89CE41-DDAF-4B7B-9D3D-EACDE74B6318Q36891753-920217D5-75E7-4B09-BEE0-B64FE84BC8F0Q37727918-1D187747-AF6D-402A-BF48-3C5308EC3F3FQ38195221-09C2D2B8-DF6F-4820-9DB4-51F7B90BF74BQ38217089-B02A8D5C-540E-4C01-98A7-720695624DB2Q38218039-921D52E5-C80A-4D3B-ABF5-A9DB5D155915Q38631018-D26015B4-B799-4F2B-B286-E5C510DAE0DDQ39067050-7DC84241-FBCA-495D-9D65-567A185EA7ECQ39768278-C9BBEA44-F84B-47D8-9E20-732E3A977517Q44548929-17E9292F-368A-4E3A-BD4D-FB651B7B2BD4Q49910917-CB0CD3D4-E05F-4DD5-85AC-3E5FE1E0A0E8Q50451773-BAE0C102-6DDD-4E4A-9480-F9ADFAC5711BQ53605182-4D0DE769-263A-4FAB-B30D-0B4BCDEB95F6Q55506186-BB2422F3-B3DC-4EFE-8639-6BD7BF898DFC
P2860
Low levels of high-density lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: A post-hoc analysis from the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug E
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Low levels of high-density lip ...... rization and Aggressive Drug E
@en
Low levels of high-density lip ...... nalysis from the COURAGE Trial
@nl
type
label
Low levels of high-density lip ...... rization and Aggressive Drug E
@en
Low levels of high-density lip ...... nalysis from the COURAGE Trial
@nl
prefLabel
Low levels of high-density lip ...... rization and Aggressive Drug E
@en
Low levels of high-density lip ...... nalysis from the COURAGE Trial
@nl
P2093
P2860
P50
P921
P1476
Low levels of high-density lip ...... rization and Aggressive Drug E
@en
P2093
Bernard R Chaitman
David J Maron
G B John Mancini
Koon K Teo
Marcin Dada
Pamela M Hartigan
Subroto Acharjee
William Kostuk
William S Weintraub
P2860
P304
P356
10.1016/J.JACC.2013.07.051
P407
P577
2013-08-21T00:00:00Z